Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00368602 · ClinicalTrials.gov registry record · Phase 2
Beta Blocker for Chronic Wound Healing
A Phase 2 study, sponsored by University of California, Davis.
- Terminated
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00368602 is a Phase 2 study that was terminated before completion, run by University of California, Davis. The registered enrollment target is 40 participants.
The verdict
NCT00368602, a Phase 2 study, was terminated before completion, sponsored by University of California, Davis.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of treatment of chronic cutaneous ulcers and burn wounds with topical beta adrenergic antagonists (Timoptic®).
Interventions
- OTHER Placebo
- DRUG Timoptic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2005-06 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00368602
The ClinicalTrials.gov registry entry for NCT00368602 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00368602 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00368602 about?
NCT00368602 is a clinical study titled "Beta Blocker for Chronic Wound Healing". The purpose of this study is to evaluate the efficacy and safety of treatment of chronic cutaneous ulcers and burn wounds with topical beta adrenergic antagonists (Timoptic®).
What is the current status of trial NCT00368602?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2005-06. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00368602?
The interventions under investigation include: Placebo (OTHER), Timoptic (DRUG).
Who is sponsoring clinical trial NCT00368602?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.